A UC HEMATOLOGIC MALIGNANCY CONSORTIUM PHASE II TRIAL OF OBINUTUZUMAB, IBRUTINIB AND VENETOCLAX IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA.

A. Zafar, N. Esteghamat, H. AbdulHaq, P. Kaesberg, R. Hoeg, A. Tsumara, S. Chen, S. Li, B. Heyman, P. Young, M. Bukari, C. Mulroney, H. Eradat, A. S. Rosenberg, J. Tuscano. A UC HEMATOLOGIC MALIGNANCY CONSORTIUM PHASE II TRIAL OF OBINUTUZUMAB, IBRUTINIB AND VENETOCLAX IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA. Hematological Oncology. 2025 Jun 16; 43(S3).

2025
https://researcherprofiles.org/profile/628480927

A. Zafar, N. Esteghamat, H. AbdulHaq, P. Kaesberg, R. Hoeg, A. Tsumara, S. Chen, S. Li, B. Heyman, P. Young, M. Bukari, C. Mulroney, H. Eradat, A. S. Rosenberg, J. Tuscano